RecruitingPhase 2NCT06861244

Embryonal Tumor With Multilayered Rosettes

PNOC031: Protocol for Embryonal Tumor With Multilayered Rosettes (ETMR)


Sponsor

University of California, San Francisco

Enrollment

70 participants

Start Date

Mar 6, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

This is an open-label, comprehensive, iterative investigation of evaluating the use of induction chemotherapy, high-dose chemotherapy, and focal radiation therapy in children with newly diagnosed Embryonal Tumor With Multilayered Rosettes (ETMR).


Eligibility

Plain Language Summary

Simplified for easier understanding

This study is researching a very rare and aggressive childhood brain tumor called ETMR (Embryonal Tumor with Multilayered Rosettes). It aims to collect data and tissue samples to better understand and treat this cancer. **You may be eligible if...** - You (or your child) have a confirmed diagnosis of ETMR, either by molecular testing or by looking at tissue under a microscope - There is enough tumor tissue available (at least 10–20 slides or a tissue block) for analysis - Depending on the treatment group (cohort), you may or may not have received prior cancer treatment **You may NOT be eligible if...** - There is not enough tumor tissue available for testing - The study chairs have not approved enrollment based on your specific situation Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

RADIATIONRadiotherapy (RT)

Undergo RT

DRUGChemotherapy Drug, Cancer - Physician's Choice

One or more of the following may be assigned by the physician (physician's choice) per standard of care guidelines upon study enrollment following surgery: Cytarabine, Carboplatin, Cisplatin, Vincristine Sulfate injection (Vincristine PFS), Topotecan Hydrochloride, Dactinomycin, Thiotepa, Filgrastim, Cyclophosphamide, or Doxorubicin Hydrochloride. Not all participants will receive all possible drug regimens.

PROCEDURENon-Investigational Surgical Resection

Undergo surgery directly before study enrollment as part of planned care.

DRUGTemozolomide

Participants assigned to or whom receive optional RT will receive concurrent temozolomide

PROCEDURETumor Tissue Sample

Tumor tissue will be collected for correlative studies

PROCEDUREBlood Sample

Blood samples will be collected for correlative studies

PROCEDURECerebrospinal Fluid (CSF) Sample

CSF samples will be collected for correlative studies


Locations(7)

University of Alabama at Birmingham

Birmingham, Alabama, United States

University of California, San Francisco

San Francisco, California, United States

Riley Hospital for Children at Indiana University Health

Indianapolis, Indiana, United States

Johns Hopkins University

Baltimore, Maryland, United States

Washington University in St. Louis

St Louis, Missouri, United States

Hackensack University Medical Center

Hackensack, New Jersey, United States

St. Jude Children's Research Hospital

Memphis, Tennessee, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06861244


Related Trials